Basilea Pharmaceutica

6 July 2021
Lisavanbulin revisited
Showing lots of promise

31 May 2021
Update on derazantinib clinical programs
Establishing optimum positioning

24 March 2021

FIDES-01 Interim results

Derazantinib differentiation apparent

6 May 2021

Ceftobiprole

Bacteraemia is the key

22 February 2021

Lisavanbulin

Lisavanbulin in Focus

16 February 2021

Full Year 2020

Solid results and more to come

21 December 2020

Derazantinib

The overlooked FGFR inhibitor

19 October 2020 

Initiation of coverage

The best is yet to come

Please subscribe to receive our research, articles and invitations as soon as they are available. Our research is classified as a ‘minor non-monetary benefit’ as defined by the Markets in Financial Instruments Directive II.

Thank you for subscribing